Home/Filings/4/0001437749-25-002688
4//SEC Filing

Schoenberg Mark 4

Accession 0001437749-25-002688

CIK 0001668243other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 11:53 AM ET

Size

20.3 KB

Accession

0001437749-25-002688

Insider Transaction Report

Form 4
Period: 2025-01-31
Schoenberg Mark
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2025-01-31+1,334146,425 total
  • Exercise/Conversion

    Ordinary Shares

    2025-01-31+3,333150,436 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-311,3340 total
    Ordinary Shares (1,334 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-313,3336,667 total
    Ordinary Shares (3,333 underlying)
  • Award

    Restricted Stock Units

    2025-01-31+20,00020,000 total
    Ordinary Shares (20,000 underlying)
  • Sale

    Ordinary Shares

    2025-01-31$11.14/sh759$8,455145,666 total
  • Sale

    Ordinary Shares

    2025-01-31$11.14/sh1,896$21,121147,103 total
  • Sale

    Ordinary Shares

    2025-01-31$11.14/sh1,896$21,121148,540 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-313,3333,334 total
    Ordinary Shares (3,333 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2025-01-31+3,333148,999 total
Footnotes (6)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
  • [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
  • [F3]The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
  • [F4]The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
  • [F5]The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
  • [F6]1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028.

Issuer

UroGen Pharma Ltd.

CIK 0001668243

Entity typeother

Related Parties

1
  • filerCIK 0001763581

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 11:53 AM ET
Size
20.3 KB